Sign In
Buy SNY
$44.38
+2.01 (+4.74%)
At Close: Jun 04, 2026
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)
03:16am, Wednesday, 25'th May 2022
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
The Zacks Analyst Blog Highlights Alphabet, UnitedHealth Group, Costco Wholesale, Cisco Systems and Sanofi
09:34am, Tuesday, 24'th May 2022 Zacks Investment Research
Alphabet, UnitedHealth Group, Costco Wholesale, Cisco Systems and Sanofi have been included in this Analyst Blog.
Top Stock Reports for Alphabet, UnitedHealth & Costco
04:29pm, Monday, 23'rd May 2022 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), UnitedHealth Group Incorporated (UNH), and Costco Wholesale Corporation (COST).
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication
02:20pm, Monday, 23'rd May 2022 Zacks Investment Research
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication
12:03pm, Monday, 23'rd May 2022
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
This Safe Stock Is Dirt Cheap -- and It's Beating the Market
12:03pm, Friday, 20'th May 2022 The Motley Fool
There's a lot to like about this big pharma juggernaut.
This Safe Stock Is Dirt Cheap -- and It's Beating the Market
08:03am, Friday, 20'th May 2022
There's a lot to like about this big pharma juggernaut.
Sanofi ordered to compensate French family for epilepsy drug side effects
07:53am, Saturday, 14'th May 2022
A French court has ordered Sanofi to pay more than 400,000 euros ($416,440) in damages to a family whose child suffered from a form of autism caused by its epilepsy drug Valproate, saying the drugmake
Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug
02:20pm, Thursday, 12'th May 2022 Zacks Investment Research
The FDA accepts Regulus' (RGLS) IND application for RGLS8429 to treat autosomal dominant polycystic kidney disease. The company plans to begin a phase I study in second-quarter 2022. Stock up.
How Novo Nordisk Will Protect Insulin Sales
11:23am, Thursday, 12'th May 2022 The Motley Fool
Advancing insulin technology promises a better patient experience.
Is Dario (DRIO) Health Eating Teladoc's (TDOC) Lunch? Q1 Earnings on Tap Thursday After Meeting with Sanofi (SNY)
01:35pm, Wednesday, 11'th May 2022
Teladoc (NYSE: TDOC) stock recently cratered to a new 52 week low following it's Q1 report. Some of it's shortfall was attributed by management to longer sales cycles in the insurer and employer space
Why GSK May Have Bet Too Big on a Pandemic Pipeline
11:57am, Saturday, 07'th May 2022 The Motley Fool
Its late-stage pipeline is heavily weighted toward pandemic treatments.
Tracking Ken Fisher's Fisher Asset Management Portfolio - Q1 2022 Update
05:44am, Saturday, 07'th May 2022 Seeking Alpha
Ken Fisher’s 13F portfolio value decreased from ~$179B to ~$165B in Q1 2022. Find more details here...
3 Top Biotech Stocks to Buy Right Now
02:45pm, Friday, 06'th May 2022 The Motley Fool
These three pharma stocks each pay market-beating dividends to shareholders.
3 Top Biotech Stocks to Buy Right Now
10:45am, Friday, 06'th May 2022
These three pharma stocks each pay market-beating dividends to shareholders.
